Aaron Deep Email & Phone Number

Served as project leader for the structure-activity relationship (SAR) project, led several other drug discovery efforts to identify lead and optimize lead molecules for multiple programs and played key role in joint projects between Alnylam, companies and academic labs to explore new therapeutic potential • Talented mentor and leader, led an integrated biology and chemistry team and collaborated with other teams• Established a highly effective cell culture and high throughput screening… Show more Served as project leader for the structure-activity relationship (SAR) project, led several other drug discovery efforts to identify lead and optimize lead molecules for multiple programs and played key role in joint projects between Alnylam, companies and academic labs to explore new therapeutic potential • Talented mentor and leader, led an integrated biology and chemistry team and collaborated with other teams• Established a highly effective cell culture and high throughput screening laboratories • Successfully managed diverse research activities that supported development programs by identifying and optimizing anti-cancer, anti-metabolic, anti-inflammatory and anti-viral leads• Successfully improved the properties of drug molecules by enhancing the potency, specificity, stability, uptake and the tolerability. Show less

• Initiated and co-led Alnylam’s first exploratory therapeutic program, targeting ApoB for cardiovascular disease, and succeeded in demonstrating that the drug molecule can be delivered systemically to suppress a disease-related gene using a therapeutically relevant mode of admin.• Played a key role in Alnylam’s most advanced therapeutic program, the Respiratory Syncytial Virus (RSV) program, where RSV is being targeted directly with locally administered siRNA for the treatment and… Show more • Initiated and co-led Alnylam’s first exploratory therapeutic program, targeting ApoB for cardiovascular disease, and succeeded in demonstrating that the drug molecule can be delivered systemically to suppress a disease-related gene using a therapeutically relevant mode of admin.• Played a key role in Alnylam’s most advanced therapeutic program, the Respiratory Syncytial Virus (RSV) program, where RSV is being targeted directly with locally administered siRNA for the treatment and prevention of RSV respiratory infection, a potentially fatal disease in newborns and adult lung transplant patients• Conducted in vitro/ in vivo studies to evaluate anti- RSV molecules from discovery to the drug development and wrote SOP and five FDA reports related to IND filing Show less